159 related articles for article (PubMed ID: 25371406)
1. Lack of utility of SDHB mutation testing in adrenergic metastatic phaeochromocytoma.
Sue M; Martucci V; Frey F; Lenders JM; Timmers HJ; Peczkowska M; Prejbisz A; Swantje B; Bornstein SR; Arlt W; Fassnacht M; Beuschlein F; Robledo M; Pacak K; Eisenhofer G
Eur J Endocrinol; 2015 Feb; 172(2):89-95. PubMed ID: 25371406
[TBL] [Abstract][Full Text] [Related]
2. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis.
van Nederveen FH; Gaal J; Favier J; Korpershoek E; Oldenburg RA; de Bruyn EM; Sleddens HF; Derkx P; Rivière J; Dannenberg H; Petri BJ; Komminoth P; Pacak K; Hop WC; Pollard PJ; Mannelli M; Bayley JP; Perren A; Niemann S; Verhofstad AA; de Bruïne AP; Maher ER; Tissier F; Méatchi T; Badoual C; Bertherat J; Amar L; Alataki D; Van Marck E; Ferrau F; François J; de Herder WW; Peeters MP; van Linge A; Lenders JW; Gimenez-Roqueplo AP; de Krijger RR; Dinjens WN
Lancet Oncol; 2009 Aug; 10(8):764-71. PubMed ID: 19576851
[TBL] [Abstract][Full Text] [Related]
3. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.
Eisenhofer G; Lenders JW; Siegert G; Bornstein SR; Friberg P; Milosevic D; Mannelli M; Linehan WM; Adams K; Timmers HJ; Pacak K
Eur J Cancer; 2012 Jul; 48(11):1739-49. PubMed ID: 22036874
[TBL] [Abstract][Full Text] [Related]
4. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.
Zelinka T; Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Reynolds JC; Ling A; Eisenhofer G; Lazúrová I; Adams KT; Whatley MA; Widimsky J; Pacak K
Endocr Relat Cancer; 2008 Mar; 15(1):311-23. PubMed ID: 18310297
[TBL] [Abstract][Full Text] [Related]
5. Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas.
Benn DE; Croxson MS; Tucker K; Bambach CP; Richardson AL; Delbridge L; Pullan PT; Hammond J; Marsh DJ; Robinson BG
Oncogene; 2003 Mar; 22(9):1358-64. PubMed ID: 12618761
[TBL] [Abstract][Full Text] [Related]
6. Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas.
Wallace PW; Conrad C; Brückmann S; Pang Y; Caleiras E; Murakami M; Korpershoek E; Zhuang Z; Rapizzi E; Kroiss M; Gudziol V; Timmers HJ; Mannelli M; Pietzsch J; Beuschlein F; Pacak K; Robledo M; Klink B; Peitzsch M; Gill AJ; Tischler AS; de Krijger RR; Papathomas T; Aust D; Eisenhofer G; Richter S
J Pathol; 2020 Aug; 251(4):378-387. PubMed ID: 32462735
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations.
Bernardo-Castiñeira C; Valdés N; Celada L; Martinez ASJ; Sáenz-de-Santa-María I; Bayón GF; Fernández AF; Sierra MI; Fraga MF; Astudillo A; Jiménez-Fonseca P; Rial JC; Hevia MÁ; Turienzo E; Bernardo C; Forga L; Tena I; Molina-Garrido MJ; Cacho L; Villabona C; Serrano T; Scola B; Chirivella I; Del Olmo M; Menéndez CL; Navarro E; Tous M; Vallejo A; Athimulam S; Bancos I; Suarez C; Chiara MD
J Clin Endocrinol Metab; 2019 Nov; 104(11):5673-5692. PubMed ID: 31216007
[TBL] [Abstract][Full Text] [Related]
8. Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours.
Srirangalingam U; Khoo B; Walker L; MacDonald F; Skelly RH; George E; Spooner D; Johnston LB; Monson JP; Grossman AB; Drake WM; Akker SA; Pollard PJ; Plowman N; Avril N; Berney DM; Burrin JM; Reznek RH; Kumar VK; Maher ER; Chew SL
Endocr Relat Cancer; 2009 Jun; 16(2):515-25. PubMed ID: 19208735
[TBL] [Abstract][Full Text] [Related]
9. Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement.
Taïeb D; Nölting S; Perrier ND; Fassnacht M; Carrasquillo JA; Grossman AB; Clifton-Bligh R; Wanna GB; Schwam ZG; Amar L; Bourdeau I; Casey RT; Crona J; Deal CL; Del Rivero J; Duh QY; Eisenhofer G; Fojo T; Ghayee HK; Gimenez-Roqueplo AP; Gill AJ; Hicks R; Imperiale A; Jha A; Kerstens MN; de Krijger RR; Lacroix A; Lazurova I; Lin FI; Lussey-Lepoutre C; Maher ER; Mete O; Naruse M; Nilubol N; Robledo M; Sebag F; Shah NS; Tanabe A; Thompson GB; Timmers HJLM; Widimsky J; Young WJ; Meuter L; Lenders JWM; Pacak K
Nat Rev Endocrinol; 2024 Mar; 20(3):168-184. PubMed ID: 38097671
[TBL] [Abstract][Full Text] [Related]
10. Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses.
Fischer A; Kloos S; Maccio U; Friemel J; Remde H; Fassnacht M; Pamporaki C; Eisenhofer G; Timmers HJLM; Robledo M; Fliedner SMJ; Wang K; Maurer J; Reul A; Zitzmann K; Bechmann N; Žygienė G; Richter S; Hantel C; Vetter D; Lehmann K; Mohr H; Pellegata NS; Ullrich M; Pietzsch J; Ziegler CG; Bornstein SR; Kroiss M; Reincke M; Pacak K; Grossman AB; Beuschlein F; Nölting S
J Clin Endocrinol Metab; 2023 Sep; 108(10):2676-2685. PubMed ID: 36946182
[TBL] [Abstract][Full Text] [Related]
11. Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations.
King KS; Prodanov T; Kantorovich V; Fojo T; Hewitt JK; Zacharin M; Wesley R; Lodish M; Raygada M; Gimenez-Roqueplo AP; McCormack S; Eisenhofer G; Milosevic D; Kebebew E; Stratakis CA; Pacak K
J Clin Oncol; 2011 Nov; 29(31):4137-42. PubMed ID: 21969497
[TBL] [Abstract][Full Text] [Related]
12. Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes
Andrews KA; Ascher DB; Pires DEV; Barnes DR; Vialard L; Casey RT; Bradshaw N; Adlard J; Aylwin S; Brennan P; Brewer C; Cole T; Cook JA; Davidson R; Donaldson A; Fryer A; Greenhalgh L; Hodgson SV; Irving R; Lalloo F; McConachie M; McConnell VPM; Morrison PJ; Murday V; Park SM; Simpson HL; Snape K; Stewart S; Tomkins SE; Wallis Y; Izatt L; Goudie D; Lindsay RS; Perry CG; Woodward ER; Antoniou AC; Maher ER
J Med Genet; 2018 Jun; 55(6):384-394. PubMed ID: 29386252
[TBL] [Abstract][Full Text] [Related]
13. The phenotype of
Niemeijer ND; Rijken JA; Eijkelenkamp K; van der Horst-Schrivers ANA; Kerstens MN; Tops CMJ; van Berkel A; Timmers HJLM; Kunst HPM; Leemans CR; Bisschop PH; Dreijerink KMA; van Dooren MF; Bayley JP; Pereira AM; Jansen JC; Hes FJ; Hensen EF; Corssmit EPM
Eur J Endocrinol; 2017 Aug; 177(2):115-125. PubMed ID: 28490599
[TBL] [Abstract][Full Text] [Related]
14. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
[TBL] [Abstract][Full Text] [Related]
15. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study.
Schovanek J; Martucci V; Wesley R; Fojo T; Del Rivero J; Huynh T; Adams K; Kebebew E; Frysak Z; Stratakis CA; Pacak K
BMC Cancer; 2014 Jul; 14():523. PubMed ID: 25048685
[TBL] [Abstract][Full Text] [Related]
16. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency.
Richter S; Peitzsch M; Rapizzi E; Lenders JW; Qin N; de Cubas AA; Schiavi F; Rao JU; Beuschlein F; Quinkler M; Timmers HJ; Opocher G; Mannelli M; Pacak K; Robledo M; Eisenhofer G
J Clin Endocrinol Metab; 2014 Oct; 99(10):3903-11. PubMed ID: 25014000
[TBL] [Abstract][Full Text] [Related]
17. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
[TBL] [Abstract][Full Text] [Related]
18. Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location.
Eisenhofer G; Timmers HJ; Lenders JW; Bornstein SR; Tiebel O; Mannelli M; King KS; Vocke CD; Linehan WM; Bratslavsky G; Pacak K
J Clin Endocrinol Metab; 2011 Feb; 96(2):375-84. PubMed ID: 21147885
[TBL] [Abstract][Full Text] [Related]
19. Diffusion-weighted imaging (DWI) highlights SDHB-related tumours: A pilot study.
Tufton N; White G; Drake WM; Sahdev A; Akker SA
Clin Endocrinol (Oxf); 2019 Jul; 91(1):104-109. PubMed ID: 30934121
[TBL] [Abstract][Full Text] [Related]
20. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas.
Gimenez-Roqueplo AP; Favier J; Rustin P; Rieubland C; Crespin M; Nau V; Khau Van Kien P; Corvol P; Plouin PF; Jeunemaitre X;
Cancer Res; 2003 Sep; 63(17):5615-21. PubMed ID: 14500403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
